PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer

Journal of Nuclear Medicine

Volumn 56, Issue 2, 2015, Pages 293-298

  Kratochwil, Clemens ^a   Giesel, Frederik L ^a,b   Leotta, Karin ^b   Eder, Matthias ^b   Hoppe Tich, Torsten ^a   Youssoufian, Hagop ^c   Kopka, Klaus ^b   Babich, John W ^d   Haberkorn, Uwe ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c Clinical Research   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Nephroprotection; PMPA; Prostate cancer; PSMA; Radionuclide therapy

Indexed keywords

2 (PHOSPHONOMETHYL)PENTANEDIOIC ACID; GLUTARIC ACID DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOPHARMACEUTICAL AGENT; TROFOLASTAT TC 99M; UNCLASSIFIED DRUG; [[1 CARBOXY 5 [3 (4 IODOPHENYL)UREIDO]PENTYL]UREIDO]PENTANEDOIC ACID I 125; 2-(3-(1-CARBOXY-5-(3-(4-IODOBPHENYL)UREIDO)PENTYL)UREIDO)PENTANEDIOIC ACID; 2-(PHOSPHONOMETHYL)PENTANEDIOIC ACID; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; GLUTAMIC ACID DERIVATIVE; LIGAND; MEMBRANE ANTIGEN; ORGANOPHOSPHORUS COMPOUND; TECHNETIUM; TECHNETIUM 99M 1-(1-(2-(BIS(CARBOXYMETHYL)AMINO)-2-OXOETHYL)-1H-IMIDAZOL-2-YL)-2-((1-(2-(BIS(CARBOXYMETHYL)AMINO)-2-OXOETHYL)-1H-IMIDAZOL-2-YL)METHYL)-9,14-DIOXO-2,8,13,15-TETRAAZAOCTADECANE-7,12,16,18-TETRACARBOXYLIC ACID); TECHNETIUM COMPLEX; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; DRUG UPTAKE; KIDNEY CALYX; KIDNEY FUNCTION; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PROCESS OPTIMIZATION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN TARGETING; RENAL PROTECTION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; DIAGNOSTIC USE; HUMAN; KIDNEY; METABOLISM; NUDE MOUSE; SCINTISCANNING; TIME;

ANIMALS; ANTIGENS, SURFACE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATES; HUMANS; KIDNEY; LIGANDS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOPHOSPHORUS COMPOUNDS; ORGANOTECHNETIUM COMPOUNDS; RADIONUCLIDE IMAGING; TECHNETIUM; TIME FACTORS; UREA;

EID: 84922055781     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.114.147181     Document Type: Article

References (33)

1. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
2. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostatespecific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res. 2003;9:6357-6362.
3. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819-823.
4. Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001;7:27-37.
5. 177Lu. J Nucl Med. 2005;46:634-641.
6. Tagawa ST, Milowsky MI, Morris M, et al. Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19:5182-5191.
7. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 highaffinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013;54:380-387.
8. 68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40:486-495.
9. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41: 11-20.
10. Liu H, Rajasekaran AK, Moy P, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58: 4055-4060.
11. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41: 1280-1292.
12. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
13. Oehme L, Doerr W, Wust P, Kotzerke J. Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry. Nuklearmedizin. 2008;47:205-209.
14. Hillier SM, Maresca KP, Femia FJ, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69: 6932-6940.
15. Maresca KP, Hillier SM, Femia FJ, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52:347-357.
16. Hillier SM, Maresca KP, Lu G, et al. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer. J Nucl Med. 2013;54:1369-1376.
17. 99mTc/Re-labeled small molecule prostate specific membrane antigen inhibitors with novel polar chelates. Bioorg Med Chem Lett. 2013;23:1557-1563.
18. Argyrou M, Valassi A, Andreou M, Lyra M. Rhenium-188 production in hospitals, by w-188/re-188 generator, for easy use in radionuclide therapy. Int J Mol Imaging. 2013:290750.
19. Hlouchová K, Barinka C, Klusák V, et al. Biochemical characterization of human glutamate carboxypeptidase III. J Neurochem. 2007;101:682-696.
20. Pangalos MN, Neefs JM, Somers M, et al. Isolation and expression of novel human glutamate carboxypeptidases with N-acetylated a-linked acidic dipeptidase and dipeptidyl peptidase IV activity. J Biol Chem. 1999;274:8470-8483.
21. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK. Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res. 2003;63: 2645-2648.
22. Barinka C, Rinnova M, Sacha P, et al. Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem. 2002;80:477-487.
23. Ghosh A, Heston WDW. Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. Prostate. 2003;57: 140-151.
24. Rovensk á M, Hlouchová K, Sácha P, et al. Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. Prostate. 2008;68:171-182.
25. Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. Histopathology. 2007;50: 472-483.
26. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostatespecific membrane antigen. Cancer Res. 1994;54:1807-1811.
27. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 1995;62:552-558.
28. Wolf P, Freudenberg N, Bühler P, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70:562-569.
29. Jackson PF, Tays KL, Maclin KM, et al. Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem. 2001;44:4170-4175.
30. Tsukamoto T, Majer P, Vitharana D, et al. Enantiospecificity of glutamate carboxypeptidase II inhibition. J Med Chem. 2005;48:2319-2324.
31. van der Post JP, de Visser SJ, de Kam ML, et al. The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol. 2005;60:128-136.
32. Chen SR, Wozniak KM, Slusher BS, Pan HL. Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. J Pharmacol Exp Ther. 2002;300:662-667.
33. She Y, Tang Z, Lapidus RG, Wozniak KM, Scher HI, Slusher BS. 2-MPPA, a selective inhibitor of PSMA, delays prostate cancer growth and attenuates taxol-induced neuropathy in mice [abstract]. J Clin Oncol. 2005;16(suppl):8054.